The buying and selling of stock by a company’s insider give investors a sense that the stock will rise or fall in the future. PTC Therapeutics Inc shares valued at $136,656 were sold by Boulding Mark Elliott on Aug 15 ’25. At $48.58 per share, Boulding Mark Elliott sold 2,813 shares. The insider’s holdings dropped to 103,901 shares worth approximately $5.17 million following the completion of this transaction.
Also, Boulding Mark Elliott purchased 2,813 shares, netting a total of over 136,646 in proceeds.
Before that, Klein Matthew B. had sold 10,739 shares from its account. In a trade valued at $555,636, the CHIEF EXECUTIVE OFFICER traded PTC Therapeutics Inc shares for $51.74 each. Upon closing the transaction, the insider’s holdings decreased to 10,739 shares, worth approximately $16.81 million.
As published in their initiating research note from Truist on June 17, 2025, PTC Therapeutics Inc [PTCT] has been a Buy and the price target has been revised to $80. Analysts at BofA Securities upgraded the stock from ‘”a Neutral”‘ to ‘”a Buy”‘ outlook in a report released in early May. As of May 07, 2025, Citigroup has increased its “Sell” rating to a “Neutral” for PTCT. Earlier on March 11, 2025, BofA Securities upgraded its rating. Their new recommendation was “a Neutral” for PTCT stock which previously was a “an Underperform”.
Analyzing PTCT Stock Performance
On last trading session, PTC Therapeutics Inc [NASDAQ: PTCT] rose 0.65% to $49.78. The stock’s lowest price that day was $48.86, but it reached a high of $50.7 in the same session. During the last five days, there has been a surge of approximately 1.90%. Over the course of the year, PTC Therapeutics Inc shares have jumped approximately 45.77%. Shares of the company reached a 52-week high of $58.38 on 03/17/25 and a 52-week low of $35.95 on 05/06/25.
Support And Resistance Levels for PTC Therapeutics Inc (PTCT)
According to the 24-hour chart, there is a support level at 48.86, which, if violated, would cause prices to drop to 47.94. In the upper region, resistance lies at 50.70. The next price resistance is at 51.62. RSI (Relative Strength Index) is 53.22 on the 14-day chart, showing neutral technical sentiment.
Is PTC Therapeutics Inc subject to short interest?
Stocks of PTC Therapeutics Inc saw a sharp rise in short interest on 2025-08-15 jumping by 0.72 million shares to 6.5 million. Data from Yahoo Finance shows that the short interest on 2025-07-15 was 5.77 million shares. A jump of 11.15% in short interest reflects a negative sentiment towards the stock. Despite the fact that short shares comprise just 5.23 of the overall float, the days-to-cover ratio (short ratio) jumped to 5.23.
Which companies own the most shares of PTC Therapeutics Inc (PTCT)?
In terms of PTC Therapeutics Inc share price expectations, FactSet research, analysts set an average price target of 70 in the next 12 months, up nearly 41.53% from the previous closing price of $49.46. Analysts anticipate PTC Therapeutics Inc stock to reach 70 by 2025, with the lowest price target being 70. In spite of this, 7 analysts ranked PTC Therapeutics Inc stock as Hold at the end of 2025. On March 07, 2025, Scotiabank assigned a price target of “a Sector perform” to the stock and initiated coverage with a $55.
